Glycovax-002 / Glycovax Pharma - LARVOL DELTA

Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: Glycovax Pharma Inc. | Trial completion date: Aug 2024 ➔ Dec 2024 | Trial primary completion date: Apr 2024 ➔ Jun 2024

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: Glycovax Pharma Inc. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Nov 2023 ➔ Apr 2024

Enrollment closed • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Glycovax Pharma Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • IL2

Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Glycovax Pharma Inc.

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • IL2